MedTrace Logo

The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions

NCT04007055 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2026-02-13

Study results available
· View outcomes & findings →

Summary

This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.

Conditions

  • Peripheral Artery Disease
  • Clopidogrel, Poor Metabolism of
  • Peripheral Vascular Disease
  • Artery Disease
  • Peripheral Arterial Occlusive Disease

Interventions

DIAGNOSTIC_TEST

Point of care screening for HPR

HPR testing using VerifyNow testing system. HPR is defined platelet reactivity units are greater than 234

DRUG

Ticagrelor 90mg

Participants who test positive for HPR will be prescribed ticagrelor 90mg twice daily instead of standard therapy with clopidogrel 75mg daily

Sponsors & Collaborators

  • Marissa Jarosinski

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-09
Primary Completion
2023-03-28
Completion
2024-03-28
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04007055 on ClinicalTrials.gov